Last 12 months
Inside the activity.
2 purchase rows · 116 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 15 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 29 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 31 |
| Apr 2026 | 0 | 9 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 11 |
| Jul 2026 | 2 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2025 Filed Sep 16, 2025 20:56 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
SaleCommon Stock | 1,700 | $64.58 | $109,787.19 |
DisclosureSEC source: 0000874015-25-000234 · edgardoc.xml · nonDerivative · entry 2 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,130 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.53 to $64.605 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 20:56 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
Exercise / conversionCommon Stock | 1,700 | $56.78 | $96,526.00 |
DisclosureSEC source: 0000874015-25-000234 · edgardoc.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 21:05 UTC |
Baroldi JosephEVP, Chief Business Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 11,950 | $0.00 Strike: $31.80 | $0.00 |
DisclosureSEC source: 0000874015-25-000232 · edgardoc.xml · derivative · entry 4 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,700 Underlying: Common Stock · 11,950 shares Expires 2032-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 21:05 UTC |
Baroldi JosephEVP, Chief Business Officer
|
SaleCommon Stock | 11,950 | $62.16 | $742,838.29 |
DisclosureSEC source: 0000874015-25-000232 · edgardoc.xml · nonDerivative · entry 2 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,926 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.44 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 21:05 UTC |
Baroldi JosephEVP, Chief Business Officer
|
Exercise / conversionCommon Stock | 11,950 | $31.80 | $380,010.00 |
DisclosureSEC source: 0000874015-25-000232 · edgardoc.xml · nonDerivative · entry 1 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 21:04 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-25-000231 · edgardoc.xml · derivative · entry 6 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,461 Underlying: Common Stock · 20,000 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 21:04 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $56.78 | $0.00 |
DisclosureSEC source: 0000874015-25-000231 · edgardoc.xml · derivative · entry 5 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,203 Underlying: Common Stock · 1,000 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 21:04 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
SaleCommon Stock | 1,000 | $64.56 | $64,555.30 |
DisclosureSEC source: 0000874015-25-000231 · edgardoc.xml · nonDerivative · entry 4 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,130 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.50 to $64.66 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 21:04 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
Exercise / conversionCommon Stock | 1,000 | $56.78 | $56,780.00 |
DisclosureSEC source: 0000874015-25-000231 · edgardoc.xml · nonDerivative · entry 3 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 21:04 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
SaleCommon Stock | 20,000 | $64.56 | $1,291,106.00 |
DisclosureSEC source: 0000874015-25-000231 · edgardoc.xml · nonDerivative · entry 2 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,130 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.50 to $64.66 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 21:04 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
Exercise / conversionCommon Stock | 20,000 | $60.89 | $1,217,800.00 |
DisclosureSEC source: 0000874015-25-000231 · edgardoc.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 22:30 UTC |
Baroldi JosephEVP, Chief Business Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 250 | $0.00 Strike: $31.80 | $0.00 |
DisclosureSEC source: 0000874015-25-000228 · edgardoc.xml · derivative · entry 4 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,650 Underlying: Common Stock · 250 shares Expires 2032-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 22:30 UTC |
Baroldi JosephEVP, Chief Business Officer
|
SaleCommon Stock | 250 | $62.00 | $15,500.00 |
DisclosureSEC source: 0000874015-25-000228 · edgardoc.xml · nonDerivative · entry 2 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,926 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 22:30 UTC |
Baroldi JosephEVP, Chief Business Officer
|
Exercise / conversionCommon Stock | 250 | $31.80 | $7,950.00 |
DisclosureSEC source: 0000874015-25-000228 · edgardoc.xml · nonDerivative · entry 1 Baroldi Joseph · CIK 0001813775 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 22:30 UTC |
BENNETT C FRANKEVP, Chief Scientific Officer
|
SaleCommon Stock | 6,000 | $59.60 | $357,580.80 |
DisclosureSEC source: 0000874015-25-000227 · edgardoc.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · EVP, Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,679 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 13, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.25 to $59.86 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:40 UTC |
WENDER JOSEPH HDirector
|
SaleCommon Stock | 11,200 | $60.14 | $673,548.96 |
DisclosureSEC source: 0000874015-25-000223 · edgardoc.xml · nonDerivative · entry 3 WENDER JOSEPH H · CIK 0001073384 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 108,835 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 16, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.53 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:37 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $52.22 | $0.00 |
DisclosureSEC source: 0000874015-25-000219 · edgardoc.xml · derivative · entry 7 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2027-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:37 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $42.88 | $0.00 |
DisclosureSEC source: 0000874015-25-000219 · edgardoc.xml · derivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:37 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 28,000 | $60.00 | $1,680,000.00 |
DisclosureSEC source: 0000874015-25-000219 · edgardoc.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 3, 2024 Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:37 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000219 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 28,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:37 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000219 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 16,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:38 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 102,900 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-25-000221 · edgardoc.xml · derivative · entry 11 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 102,900 shares Expires 2026-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:38 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 42,030 | $0.00 Strike: $37.58 | $0.00 |
DisclosureSEC source: 0000874015-25-000221 · edgardoc.xml · derivative · entry 10 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,643 Underlying: Common Stock · 42,030 shares Expires 2033-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:38 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 27,568 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-25-000221 · edgardoc.xml · derivative · entry 9 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,173 Underlying: Common Stock · 27,568 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:38 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 31,316 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-25-000221 · edgardoc.xml · derivative · entry 8 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,741 Underlying: Common Stock · 31,316 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:38 UTC |
Monia Brett PDirector · Chief Executive Officer
|
SaleCommon Stock | 59,699 | $61.06 | $3,645,394.07 |
DisclosureSEC source: 0000874015-25-000221 · edgardoc.xml · nonDerivative · entry 7 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,009 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 13, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.61 to $61.48 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:38 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 27,568 | $32.60 | $898,716.80 |
DisclosureSEC source: 0000874015-25-000221 · edgardoc.xml · nonDerivative · entry 6 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:38 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 31,316 | $32.60 | $1,020,901.60 |
DisclosureSEC source: 0000874015-25-000221 · edgardoc.xml · nonDerivative · entry 5 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:38 UTC |
Monia Brett PDirector · Chief Executive Officer
|
SaleCommon Stock | 127,500 | $60.13 | $7,667,046.75 |
DisclosureSEC source: 0000874015-25-000221 · edgardoc.xml · nonDerivative · entry 4 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,824 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 13, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.60 to $60.57 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:38 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 42,030 | $37.58 | $1,579,487.40 |
DisclosureSEC source: 0000874015-25-000221 · edgardoc.xml · nonDerivative · entry 3 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:38 UTC |
Monia Brett PDirector · Chief Executive Officer
|
SaleCommon Stock | 16,615 | $59.12 | $982,262.19 |
DisclosureSEC source: 0000874015-25-000221 · edgardoc.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,294 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 13, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.57 to $59.55 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:38 UTC |
Monia Brett PDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 102,900 | $53.77 | $5,532,933.00 |
DisclosureSEC source: 0000874015-25-000221 · edgardoc.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:38 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $52.22 | $0.00 |
DisclosureSEC source: 0000874015-25-000220 · edgardoc.xml · derivative · entry 7 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2027-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:38 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $42.88 | $0.00 |
DisclosureSEC source: 0000874015-25-000220 · edgardoc.xml · derivative · entry 6 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2028-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:38 UTC |
KLEIN JOSEPH IIIDirector
|
SaleCommon Stock | 28,000 | $60.00 | $1,680,000.00 |
DisclosureSEC source: 0000874015-25-000220 · edgardoc.xml · nonDerivative · entry 3 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 3, 2024 Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:38 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000220 · edgardoc.xml · nonDerivative · entry 2 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 28,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:38 UTC |
KLEIN JOSEPH IIIDirector
|
Exercise / conversionCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-25-000220 · edgardoc.xml · nonDerivative · entry 1 KLEIN JOSEPH III · CIK 0001206369 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 16,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:36 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,234 | $0.00 Strike: $37.58 | $0.00 |
DisclosureSEC source: 0000874015-25-000217 · edgardoc.xml · derivative · entry 5 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,083 Underlying: Common Stock · 2,234 shares Expires 2033-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:36 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 928 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-25-000217 · edgardoc.xml · derivative · entry 4 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,440 Underlying: Common Stock · 928 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:36 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
Exercise / conversionCommon Stock | 928 | $32.60 | $30,252.80 |
DisclosureSEC source: 0000874015-25-000217 · edgardoc.xml · nonDerivative · entry 3 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:36 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
SaleCommon Stock | 3,162 | $61.02 | $192,942.71 |
DisclosureSEC source: 0000874015-25-000217 · edgardoc.xml · nonDerivative · entry 2 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,009 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 3, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.0075 to $61.045 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:36 UTC |
Devers Shannon L.EVP, Chief Human Resources Ofc
|
Exercise / conversionCommon Stock | 2,234 | $37.58 | $83,953.72 |
DisclosureSEC source: 0000874015-25-000217 · edgardoc.xml · nonDerivative · entry 1 Devers Shannon L. · CIK 0002037721 · EVP, Chief Human Resources Ofc 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:29 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 49,800 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-25-000214 · edgardoc.xml · derivative · entry 11 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,800 shares Expires 2026-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:29 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $37.58 | $0.00 |
DisclosureSEC source: 0000874015-25-000214 · edgardoc.xml · derivative · entry 10 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,942 Underlying: Common Stock · 14,000 shares Expires 2033-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:29 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 13,050 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-25-000214 · edgardoc.xml · derivative · entry 9 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,467 Underlying: Common Stock · 13,050 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:29 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
Exercise / conversionCommon Stock | 49,800 | $53.77 | $2,677,746.00 |
DisclosureSEC source: 0000874015-25-000214 · edgardoc.xml · nonDerivative · entry 7 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:29 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
SaleCommon Stock | 11,375 | $61.42 | $698,652.50 |
DisclosureSEC source: 0000874015-25-000214 · edgardoc.xml · nonDerivative · entry 6 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,330 F3 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.35 to $61.48 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5)on this Form 4. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:29 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
Exercise / conversionCommon Stock | 13,050 | $32.60 | $425,430.00 |
DisclosureSEC source: 0000874015-25-000214 · edgardoc.xml · nonDerivative · entry 5 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:29 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
SaleCommon Stock | 65,475 | $60.89 | $3,986,772.75 |
DisclosureSEC source: 0000874015-25-000214 · edgardoc.xml · nonDerivative · entry 4 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,655 F3 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 2, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.3418 to $61.34 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:29 UTC |
O'NEIL PATRICK R.EVP CLO & General Counsel
|
Exercise / conversionCommon Stock | 14,000 | $37.58 | $526,120.00 |
DisclosureSEC source: 0000874015-25-000214 · edgardoc.xml · nonDerivative · entry 3 O'NEIL PATRICK R. · CIK 0001564926 · EVP CLO & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.